BCR inhibitors improving CLL patient outcomes
Why use model systems for multiple myeloma research?
Enrique Ocio et al.
The importance of blinatumomab and inotuzumab ozogamicin in treating ALL
Anti-BCMA CAR T-cells for MM: durable clinical responses with bb2121
Myeloma XI trial: impact of MRD on treatment response in MM